Search the Newsreel

Forte Biosciences earnings on deck as $2.2 billion argenx deal nears

Forte Biosciences is set to report its second-quarter earnings, which are expected to be largely a formality as the company awaits the completion of its $2.2 billion acquisition by argenx. Analysts anticipate a loss of $1.01 per share on zero revenue for Forte. The …

Artelo Biosciences (ARTL) major holder reports 0% ownership in new 13G/A

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G/A for Artelo Biosciences (ARTL), reporting that they no longer beneficially own any common stock in the company. As of June 30, 2026, their ownership stake is 0 shares, representing 0.0% of the …

TMC Life Sciences nearly doubles profit in 4Q, proposes 0.58 sen dividend

TMC Life Sciences Berhad Posts Strong Earnings and Strengthens Balance Sheet in FY2026

Skye Bioscience (NASDAQ: SKYE) exits obesity trial, pursues Redx merger and $100M+ funding

Skye Bioscience is discontinuing its nimacimab obesity program and pursuing a merger with Redx Pharma to form Fibrx Therapeutics, Inc. This strategic shift addresses significant financial strains, as evidenced by a $23.3 million net loss and a substantial doubt about its ability to continue …

Skye Bioscience, Inc. 2026: Revenue $178.2K, EPS ($0.27) — 10-Q Summary

Skye Bioscience, Inc. reported its 2026 quarterly results, showing revenue of $178.2K and a net loss of ($10.79M), leading to a diluted loss per share of ($0.27), which is an improvement over the prior year. The company also announced the termination of its CBeyond …

Arcadia Biosciences (RKDA) Announces Second Quarter and First Half 2026 Financial Results and Business Highlights

Arcadia Biosciences (RKDA) announced its second quarter and first half 2026 financial results, highlighting a significant reduction in cash used in operating activities and a strong cash balance. The company reported flat sales for Q2 2026 due to inventory and shipping issues, which have …

Form 8K TuHURA Biosciences Inc For: 14 August By Investing.com

This article reports that TuHURA Biosciences Inc. filed a Form 8K on August 14. The filing is a standard regulatory disclosure and contains no further details within this brief report, beyond mentioning the company's stock symbol, HURA, which was up 7.39% at the time …

Twist Bioscience (TWST): EdgePoint discloses 4.21% beneficial stake in amended 13G

EdgePoint Investment Group Inc. has filed an amended Schedule 13G, disclosing a 4.21% beneficial ownership stake in Twist Bioscience Corp (TWST), totaling 2,521,635 shares as of June 30, 2026. The filing indicates EdgePoint acts as an investment manager for various funds that directly own …

EU Maintained by HC Wainwright & Co. -- Price Target Lowered to $3.50

HC Wainwright & Co. has reiterated its "Buy" rating on enCore Energy Corp (EU) but reduced its price target from $3.75 to $3.50. Despite the lowered target, the company is considered undervalued by approximately 67.9% according to its GF Value™ of $3.54, though its …

Have Cerence Insiders Been Selling Stock?

Cerence Inc. (NASDAQ:CRNC) has seen recent insider selling, with Executive VP Jennifer Salinas divesting US$230k worth of shares and President Brian Krzanich selling US$1.5m over the last year. Despite these sales, the article notes that Jennifer Salinas's sale only reduced her total holding by …

HC Wainwright Has Bearish Estimate for DTIL Q3 Earnings

Deep Track Capital reports 3.64% MBX Biosciences (MBX) stake in 13G/A

Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd., and David Kroin, has filed an amended Schedule 13G/A disclosing a beneficial ownership of 3.64% in MBX Biosciences (MBX). This group collectively holds 1,732,569 shares of common stock as of June 30, …

Why Burcon NutraScience Corporation stock went up yesterday

Chardan Capital Maintains ProMIS Neurosciences(PMN.US) With Buy Rating, Raises Target Price to $33

Chardan Capital has reiterated its Buy rating for ProMIS Neurosciences (PMN.US) and increased its price target to $33. This positive outlook suggests continued confidence in the company's prospects.

Farallon group trims Tyra Biosciences (TYRA) holdings to 6,000 shares, 0% stake

Farallon Capital Management, L.L.C., along with several related investment entities and individuals, has filed an Amendment No. 2 to a Schedule 13G/A, reporting beneficial ownership of 6,000 shares of Tyra Biosciences (TYRA) common stock, which constitutes a 0% stake as of June 30, 2026. …

Kencana Agri Limited Reports Earnings Results for the Half Year Ended June 30, 2026

Cencora (COR): Leveraging Healthcare Growth and AI-Driven Productivity

Alpha Wealth Funds, LLC, an investment management company, released its Q2 2026 letter for the "Insiders Fund". A copy of the letter is available to download here. The Fund lost 1.45% in June, while it was up 8.43% for the 2nd quarter and 0.75% …

USANA (USNA) Q2 2026 Earnings Call Transcript

BioHarvest Sciences Inc. (NASDAQ:BHST) Just Reported And Analysts Have Been Cutting Their Estimates

TuHURA Bios reports Q2 2026: $1.0M cash, R&D $6.6M, $50M credit facility extends runway

TuHURA Bios reported its Q2 2026 results, showing $1.0 million in cash and cash equivalents and R&D expenses of $6.6 million. The company secured a new $50 million term credit facility from its largest shareholder, extending its cash runway into 2028. This credit facility …

Cutting-edge drug quells insatiable desire to eat. Experts warn it could be tied to deaths

Neurocrine's drug, Vykat XR, designed to treat the insatiable appetite associated with Prader-Willi Syndrome (PWS), is facing safety warnings following seven deaths. Patient organizations and doctors are calling for more research into the drug's safety, emphasizing that PWS patients often have multiple other health …

Achieve Life Sciences, Inc. (NASDAQ:ACHV): Is Breakeven Near?

Achieve Life Sciences, Inc. (NASDAQ:ACHV) is a late-stage pharmaceutical company developing cytisinicline for nicotine independence. Despite widening losses to US$114m, analysts project the company to reach breakeven by 2028, with an anticipated 69% year-on-year growth. The company currently has negative equity on its balance …

Benchmark Electronics, Inc. $BHE Shares Sold by Vest Financial LLC

Transtech Optelecom Launches HK$280 Million Share Placement Under General Mandate

Minerva Neurosciences (NASDAQ:NERV) Downgraded to Strong Sell Rating by Zacks Research

Zacks Research has downgraded Minerva Neurosciences (NASDAQ:NERV) to a "strong sell" rating, citing weak earnings forecasts despite the company beating Q2 analyst expectations. The biopharmaceutical company's shares opened at $3.92, significantly below its 52-week high, and institutional investors hold a 34.56% stake. Analysts project …

IREDA vs Inox Wind: Renewable Energy Stocks Down 7%, Buy The Dip Or Stay Away?

Citi Sticks to Their Buy Rating for Edwards Lifesciences (EW)

Tencent Music Entertainment Group (NYSE:TME) Stock Rating Lowered by Nomura

Nomura has downgraded Tencent Music Entertainment Group (NYSE:TME) from a "strong buy" to a "hold" rating, reflecting a broader cautious sentiment among analysts. The stock, which opened at $8.65, has a consensus "hold" rating and an average price target of $17.21. Institutional investors own …

Legence Corp. Class A Common stock (NASDAQ: LGN) Share Price, LGN Stock News, LGN Share Price & Updates

This page provides an overview of Legence Corp. Class A Common stock (NASDAQ: LGN), including its current share price, recent news, and financial data. It offers details on fundamental metrics, active day range, and 52-week range. The article also lists analyst recommendations and links …

Legence Corp. Class A Common stock Q2 2026 Earnings Call Summary

Legence Corp. reported strong Q2 2026 results with nearly 60% organic revenue growth, primarily driven by the data center and technology market, and achieved a record $5.7 billion backlog. The company raised its full-year 2026 revenue guidance to $4.7-$4.8 billion and is actively pursuing …

Tencent Music (TME): Tencent Holdings reports 55.5% beneficial ownership and control structure

Tencent Holdings Limited and its subsidiary, Min River Investment Limited, have reported a 55.5% beneficial ownership in Tencent Music Entertainment Group's Class A Ordinary Shares. This includes Min River's Class B stake, voting power over certain minority shareholders' Class A shares, and shares held …

Gilead Sciences, Inc. $GILD Shares Bought by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. increased its stake in Gilead Sciences by 10.9% in the second quarter, now holding 926,242 shares valued at $117 million. This move comes as Gilead reported strong quarterly revenue of $7.80 billion, exceeding analyst expectations, and announced a …

Monument Capital Management Decreases Stake in Gilead Sciences, Inc. $GILD

Monument Capital Management significantly reduced its stake in Gilead Sciences by 56.1% in the second quarter, selling over 15,000 shares. Despite this, institutional investors collectively own 83.67% of the company, and analysts maintain a "Moderate Buy" consensus with an average price target of $158.04. …

Minerva Neurosciences, Inc (NASDAQ:NERV) Given Consensus Recommendation of "Reduce" by Brokerages

Minerva Neurosciences, Inc (NASDAQ:NERV) has received a "Reduce" consensus rating from brokerages, with an average 12-month price target of $10.50. This comes as near-term earnings expectations have significantly deteriorated, with HC Wainwright cutting its fiscal 2026 and 2027 EPS estimates, although it projects profitability …

Balyasny Asset Management (NERV) discloses 9.99% Minerva Neurosciences ownership via shares and warrants

Balyasny Asset Management L.P. and its affiliates have reported a beneficial ownership of 9.99% in Minerva Neurosciences, Inc. (NERV). This stake comprises 4,654,212 shares, including 4,257,000 shares held directly by Atlas Private Holdings (Cayman) Ltd. and 397,212 shares exercisable from 13,500 warrants. The warrants …